UA124768C2 - Депо-препарат - Google Patents

Депо-препарат Download PDF

Info

Publication number
UA124768C2
UA124768C2 UAA201900958A UAA201900958A UA124768C2 UA 124768 C2 UA124768 C2 UA 124768C2 UA A201900958 A UAA201900958 A UA A201900958A UA A201900958 A UAA201900958 A UA A201900958A UA 124768 C2 UA124768 C2 UA 124768C2
Authority
UA
Ukraine
Prior art keywords
composition
weight
amount
sirolimus
present
Prior art date
Application number
UAA201900958A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вілма Тамраз
Вилма Тамраз
Хуей-Чінґ Лін Су
Хуей-Чинг Лин Су
Вейци Линь
Кадзухіто Ямада
Кадзухито Ямада
Наокі Мацумото
Наоки МАЦУМОТО
Сринівасу Мудумба
Сринивасу Мудумба
Комей Окабе
Original Assignee
Дьюрект Корпорейшн
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дьюрект Корпорейшн, Сантен Фармасьютикал Ко., Лтд. filed Critical Дьюрект Корпорейшн
Publication of UA124768C2 publication Critical patent/UA124768C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/02—Monohydroxylic acyclic alcohols
    • C07C31/08—Ethanol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/12—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
UAA201900958A 2016-06-30 2017-06-29 Депо-препарат UA124768C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356613P 2016-06-30 2016-06-30
US201662440658P 2016-12-30 2016-12-30
PCT/US2017/039968 WO2018005777A1 (en) 2016-06-30 2017-06-29 Depot formulations

Publications (1)

Publication Number Publication Date
UA124768C2 true UA124768C2 (uk) 2021-11-17

Family

ID=60786467

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201900958A UA124768C2 (uk) 2016-06-30 2017-06-29 Депо-препарат

Country Status (15)

Country Link
US (2) US10668011B2 (enExample)
EP (1) EP3478285A4 (enExample)
JP (2) JP7051721B2 (enExample)
KR (1) KR20190025635A (enExample)
CN (2) CN115645399A (enExample)
AU (2) AU2017290143A1 (enExample)
BR (1) BR112018077259A2 (enExample)
CA (1) CA2972296A1 (enExample)
IL (1) IL263714A (enExample)
MX (1) MX387477B (enExample)
PH (1) PH12018502615A1 (enExample)
SG (1) SG11201810618QA (enExample)
TW (1) TWI765898B (enExample)
UA (1) UA124768C2 (enExample)
WO (2) WO2018005777A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2979971A1 (en) * 2015-03-18 2016-09-22 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
EP3478285A4 (en) 2016-06-30 2020-07-22 Durect Corporation DEPOSIT FORMULATIONS
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
CA3097927A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
MX2020011535A (es) * 2018-05-01 2020-11-24 Chibi Inc Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
CA3141337A1 (en) 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
CN113117049A (zh) * 2019-12-31 2021-07-16 齐鲁制药有限公司 一种索玛鲁肽原位凝胶制剂及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
KR970007322B1 (ko) 1991-12-19 1997-05-07 미쓰이도오아쓰 가가쿠 가부시키가이샤 폴리히드록시 카르복실산 및 그 제조방법
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
DK1006935T3 (da) * 1995-06-07 2005-06-06 Durect Corp Styret afgivelsessystem med en væske med höj viskositet
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
JP4724354B2 (ja) 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
US8501215B2 (en) 2002-07-31 2013-08-06 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
JP2006511475A (ja) 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
BR0315304A (pt) 2002-11-06 2005-08-16 Alza Corp Formulações com depósito para liberação controlada
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
CA2518791A1 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell-schedule dependent anticancer agents
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2006039336A2 (en) 2004-10-01 2006-04-13 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2602525A1 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
CN1973822A (zh) 2006-12-20 2007-06-06 山东蓝金生物工程有限公司 一种含雷帕霉素的抗癌组合物
ES2447516T3 (es) 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
JP5599705B2 (ja) 2007-05-18 2014-10-01 デュレクト コーポレーション 改良されたデポー製剤
WO2009023877A2 (en) * 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
MX347014B (es) * 2010-11-24 2017-04-07 Durect Corp Composición para administración de fármaco biodegradable.
EP2782590A4 (en) 2011-11-23 2016-08-03 Durect Corp BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS
JP6282231B2 (ja) 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
CN109602692B (zh) * 2013-03-11 2022-11-04 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
AU2014233462A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with thixotropy and enhanced dissolution reproducibility and stability
JP6530744B2 (ja) 2013-05-24 2019-06-12 アイコン バイオサイエンス インコーポレイテッド 白内障手術後の炎症における徐放性デキサメタゾンの使用
CN107249570B (zh) 2014-11-21 2022-08-09 丹麦技术大学 用于局部药物释放的凝胶制剂
CA2979971A1 (en) 2015-03-18 2016-09-22 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
JP6872322B2 (ja) 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
EP3478285A4 (en) 2016-06-30 2020-07-22 Durect Corporation DEPOSIT FORMULATIONS
ES2944576T3 (es) 2017-01-06 2023-06-22 Santen Pharmaceutical Co Ltd Administración intratumoral de sirólimus para el tratamiento del cáncer de próstata

Also Published As

Publication number Publication date
IL263714A (en) 2019-01-31
SG11201810618QA (en) 2019-01-30
MX387477B (es) 2025-03-18
TW201811374A (zh) 2018-04-01
CN109310680B (zh) 2022-11-01
TWI765898B (zh) 2022-06-01
EP3478285A4 (en) 2020-07-22
BR112018077259A2 (pt) 2019-06-18
JP7051721B2 (ja) 2022-04-11
CN109310680A (zh) 2019-02-05
CN115645399A (zh) 2023-01-31
AU2023202823A1 (en) 2023-05-25
US20200352852A1 (en) 2020-11-12
JP2019526532A (ja) 2019-09-19
MX2018016424A (es) 2019-08-12
US10668011B2 (en) 2020-06-02
JP2022088568A (ja) 2022-06-14
CA2972296A1 (en) 2017-12-30
KR20190025635A (ko) 2019-03-11
US20180000729A1 (en) 2018-01-04
WO2019133735A1 (en) 2019-07-04
AU2017290143A1 (en) 2019-02-21
EP3478285A1 (en) 2019-05-08
WO2018005777A1 (en) 2018-01-04
PH12018502615A1 (en) 2019-09-30

Similar Documents

Publication Publication Date Title
UA124768C2 (uk) Депо-препарат
CA2635797C (en) Stable formulations, and methods of their preparation and use
US12329859B2 (en) Bioerodible drug delivery devices
US20080152708A1 (en) High viscosity liquid controlled delivery system and medical or surgical device
US20200383957A1 (en) Depot formulations
KR102696721B1 (ko) 약물의 장기간 지속적인 투여를 위한 액체 폴리머 전달 시스템
KR20070104931A (ko) 안구 치료용 제제
KR20130124415A (ko) 편리하게 이식가능한 서방형 약물 조성물
JP2008533204A (ja) 病気又は症状の治療のためのドラッグ送達システム
WO2018126049A1 (en) Depot formulations
AU2013200089B2 (en) Stable formulations, and methods of their preparation and use
CA3146064A1 (en) Long-acting formulations and vehicles